Bifogade filer
Third US patent strengthens patent protection for Ascelia Pharma's Oncoral (daily tablet irinotecan)
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Ascelia Pharma AB (publ) (ticker: ACE) announced today the decision of the US Patent and Trademark Office (USPTO) to allow the issuance of a third patent covering the composition of Oncoral.
Ascelia Pharma has received a positive Notice of Allowance from the United States Patent and Trademark Office (USPTO) for United States patent application no. 17/865,734 for Oncoral. Oncoral is Ascelia Pharma’s investigational oral daily irinotecan chemotherapy with potential to offer both better efficacy and safety compared to intravenous high-dose chemotherapy infusions at the hospital.
“We are very pleased with the continued development of the patent portfolio for Oncoral and view the decision of the USPTO as recognition of the innovation behind our novel oral formulation of irinotecan. The opportunity to strengthen the patent protection for Oncoral adds further value to the development and commercialization opportunities for Oncoral and for Ascelia Pharma”, said Julie Waras Brogren, Deputy CEO and Chief Commercial Officer of Ascelia Pharma.
The new patent covers the tablet composition and will provide protection until 2035 plus potential extension in the US. It broadens the scope of Ascelia Pharma’s patent protection for Oncoral beyond the already-granted US patents US 10,143,657 and US 11,419,825, which broadly cover the solid oral composition of Oncoral as well as the method of using Oncoral. Outside the US, Oncoral is covered by patents in selected European countries and in Japan, China and Canada.